Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (March 2018)

Friday, May 25, 2018

Between January and March 2018, Russia imported 113.9 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 0.2% higher than that of the same period of 2017, and 24.4 bln RUB worth of in-bulk pharmaceuticals, which is in monetary terms 18.5% higher than that of the same period of 2017. In total, the dynamics are 3%.

In March 2018, Russia imported 43.6 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 12.6% lower than that of March 2017 (lowest since March 2016), and 10.3 bln RUB worth of in-bulk drugs, which is 70.4% higher than that of March 2017. While the dynamics of the import of in-bulk drugs may seem spectacular, the dynamics were negative in January and February, which is compensated by the March results.

In physical terms, Russia imported 168.6 mln units of ready-made drugs, which is 13% lower than that of March 2017. If calculated in MDU (minimum dosage units), the dynamics are 0.9% for March and 0.2% for Q1 2018. However, thanks to the growing import of in-bulk drugs, the total dynamics for Q1 are 1.7%. The dynamics for the import of in-bulk drugs are 13.4% if calculated in MDU.

The leaders in the import of in-bulk pharmaceuticals in March are Sanofi and Merck Group. Sanofi has increased its import by more than 6 times over the year, thanks to Aubagio, Cerezyme, Toujeo, and Pentaxim. Merck Group has increased its import by nearly 3 times, thanks to Concor and Rebif.

Read more about pharmaceutical drug import to Russia (February results): http://rncph.com/news/18_04_2018

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – March 2018)

Share: